Trials / Completed
CompletedNCT00038597
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- M.D. Anderson Cancer Center · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this research is to see if giving the drug SCH66336 by mouth can improve the disease in patients with chronic or accelerated phase CML. The safety of this treatment will also be studied.
Detailed description
Objectives for this study are two-fold: 1. To determine the efficacy of SCH66336 in patients with chronic phase and accelerated phase CML in relation to response rate, duration of response, and survival. 2. To assess the toxicity of SCH66366 in these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SCH66336 |
Timeline
- Start date
- 2001-04-30
- Primary completion
- 2004-05-07
- Completion
- 2004-05-07
- First posted
- 2002-06-04
- Last updated
- 2018-10-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00038597. Inclusion in this directory is not an endorsement.